1. Home
  2. Live Updates
  3. Multiple myeloma

Live Breaking News & Updates on Multiple myeloma

Stay informed with the latest breaking news from Multiple myeloma on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Multiple myeloma and stay connected to the pulse of your community

Dr Usmani on the Design of the CARTITUDE-4 Trial in Multiple Myeloma

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the design of the phase 3 CARTITUDE-4 trial in multiple myeloma.

Saadz-usmani , Memorial-sloan-kettering-cancer-center , Myeloma-service , Emorial-sloan-kettering-cancer-center , Onclive-tv , Multiple-myeloma ,

U.S. Gene Therapy Market Size, Share & Trends Analysis

Dublin, April 23, 2024 (GLOBE NEWSWIRE) -- The

United-states , Dublin , Ireland , Vertex-pharmaceuticals-incorporated , Company-market-position-analysis , Route-of-administration , Sarepta-therapeutics-inc , Krystal-biotech-inc , Route-of-administration-business-analysis , Amgen-inc , Merck-co

U.S. Gene Therapy Market Size, Share & Trends Analysis Report 2024-2030: Robust Pipeline And Growing Prevalence Of Target Diseases Fueling Growth And ...

U.S. Gene Therapy Market Size, Share & Trends Analysis Report 2024-2030: Robust Pipeline And Growing Prevalence Of Target Diseases Fueling Growth And ...
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

Dublin , Ireland , Krystal-biotech-inc , Gilead-sciences-inc , Bristol-myers-squibb-company , Vertex-pharmaceuticals-incorporated , Sarepta-therapeutics-inc , Amgen-inc , Merck-co , Therapy-market-size , Trends-analysis-report

CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed

CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy Expanded indication for this one-time infusion may provide pati...

Spain , Beerse , Region-flamande , Belgium , Edmond-chan , Drug-administration , European-union , Committee-for-orphan-medicinal-products , Janssen-cilag-international , European-medicines-agency , European-commission , Johnson

Study points to racial and social barriers that block treatment for multiple myeloma

Study points to racial and social barriers that block treatment for multiple myeloma
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

United-states , California , American , Theresa-keegan , Naseems-esteghamat , Naseem-esteghamat , A-uc-davis-health , Marrow-transplant-research , International-blood , Uc-davis-comprehensive-cancer-center , Clinical-lymphoma , California-cancer-registry

Johnson & Johnson : CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy

Media contact:




Investor contact:




...

Spain , United-states , China , Belgium , Beerse , Region-flamande , Chinese , American , Edmond-chan , Jenni-mildon , Ciltacabtagene-autoleucel , European-commission-grants-conditional-approval

European Commission Approves Cilta-Cel for Relapsed/Refractory Multiple Myeloma

Cilta-cel has received approval from the European Commission for multiple myeloma that is relapsed or refractory to at least 1 prior line of therapy.

Spain , Edmond-chan , Johnson-company , Johnson , European-commission , Therapeutic-area-lead-for-haematology-at-janssen-cilag , San-miguel , Translational-medicine , Universidad-de-navarra , Area-lead , Janssen-cilag-limited , Multiple-myeloma

Dr Jagannath on the Mechanism of Action of Linvoseltamab in R/R Multiple Myeloma

Sundar Jagannath, MBBS, discusses the mechanism of action and tolerability of linvoseltamab in patients with relapsed/refractory multiple myeloma.

Sundar-jagannath , Tisch-cancer-institute , Multiple-myeloma , Mount-sinai ,

Natural Killer (NK) Cell Therapy Pipeline Research Report

Dublin, April 19, 2024 (GLOBE NEWSWIRE) -- The

Dublin , Ireland , Sweden , Pharma-monalizumab , Kiadis-pharma , Persongen-biotherapeutics , Route-of-administration , Cellprotect-nordic-pharmaceuticals , Altor-bioscience-corporation , Vecura-at-karolinska-university-hospital , Karolinska-university-hospital-in-huddinge , Natural-killer

Sharon Timmons Puls | Obituary | Clinton Herald

Sharon Timmons Puls passed away. This is the full obituary where you can share condolences and memories. Published in the Clinton Herald on 2024-04-12.

Atlanta , Georgia , United-states , Colorado , Prince-of-peace-church , Clinton-high-school , Iowa , Longmont , Mississippi , Kay-frahm , Judy-hammett , Parker-mccollough